论文部分内容阅读
目的:探讨乳腺化生性癌的病理特征、复发和生存情况。方法:选取我院于2002年1月至2015年12月期间收治的7例乳腺化生性癌患者临床病历资料进行回顾性分析,讨论乳腺化生性癌的病理特点和鉴别诊断、组织起源以及治疗预后等。结果:7例乳腺化生性癌PR、ER和HER-2均显示为阴性,广谱CK则显示为阳性;所有入选患者均显示EGFR阳性,其中有3例患者显示p53阳性,4例患者显示CK5/6阳性。此外,3例患者经腋窝淋巴结清扫后显示有2例患者出现腋窝淋巴结转移,4例患者经前哨淋巴结活检后结果:显示无癌转移。结论:乳腺化生性癌在临床上属于乳腺癌中较为罕见的亚型,其生物学行为和生存预后均不佳,HER-2和PR、ER等多显示为阴性,容易复发,目前主要治疗方法:为在手术治疗的基础上加以放射治疗。
Objective: To investigate the pathological features, recurrence and survival of mastocarcinoma. Methods: The clinical data of 7 cases of mastocystic carcinoma treated in our hospital from January 2002 to December 2015 were retrospectively analyzed to discuss the pathological features, differential diagnosis, histological origin and treatment prognosis of mastocarcinoma Wait. Results: PR, ER and HER-2 were all negative and broad-spectrum CK was positive in all the 7 cases. All of the selected patients showed positive EGFR, of which 3 showed p53 positive and 4 showed CK5 / 6 positive. In addition, axillary lymph node metastases occurred in 2 of 3 patients after axillary lymph node dissection and in 4 patients after sentinel lymph node biopsy: no metastasis was found. Conclusions: Breast cancer is clinically a rare subtype of breast cancer, and its biological behavior and survival prognosis are not good, HER-2 and PR, ER and more showed negative, easy to relapse, the current main treatment : For radiotherapy based on surgical treatment.